March 7, 2008 - Siemens Healthcare launched the DCA Vantage Analyzer, a point-of-care (POC) diabetes patient management platform reporting glycosylated hemoglobin (HbA1c), microalbumin/creatinine and albumin-to-creatinine results for diabetes management.

GE's SnapShot Pulse offers improved dose reduction results for both diagnostic cardiac and neuro perfusion CT exams and has been reportedly proven to reduce a patient's radiation exposure by up to 83 percent.

Accompanied by the SnapShot Pulse will be the GE's LightSpeed VCT XT, a CT scanner that reportedly maintains high-quality imaging while reducing patients' radiation exposure by up to 70 percent for diagnostic cardiac scans.

Siemens Healthcare now has available the DCA Vantage Analyzer, a point-of-care (POC) diabetes patient management platform reporting glycosylated hemoglobin (HbA1c), microalbumin/creatinine and albumin-to-creatinine results for diabetes management.

March 5, 2008 - The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA) has issued a positive opinion recommending approval of the 300 mg tablet of the antiplatelet Plavix (clopidogrel bisulfate), a treatment intended to promote early use of Plavix in acute coronary syndrome patients (ACS).

March 6, 2008 - Axellis Ltd., the UK- and US-based medical technology company, has completed acquisitions of three software solutions business as part of the company’s strategy to position itself as a global provider of specialist hardware and software solutions for oncology and cardiology.

The companies that Axellis purchased have a full suite of complimentary technologies that will support and add value to today’s Oncology and cardiology programmes.

March 6, 2008 - The third annual Medical Device Regulatory, Reimbursement and Compliance Congress (Device Congress) to be held on the campus of Harvard University March 26-28 2008, will address how to satisfy the FDA, CMS, OIG, Congress, payers, providers and patients.

March 5, 2008 - Edwards Lifesciences Corp. reported that the first three human implants of the next-generation Edwards transcatheter aortic heart valve were performed at St. Paul's Hospital in Vancouver, British Columbia, marking the progression of minimally-invasive valve therapy.

February 5, 2008 - Doctors completed the first implant of Boston Scientific’s COGNIS cardiac resynchronization therapy defibrillator (CRT-D), which reportedly represents an entirely new platform to treat heart failure.

March 4, 2008 – MEDRAD sales revenues grew to $525 million in 2007, an increase of 10 percent over the previous year, which is expected to grow further should the merger with Possis be completed.

March 3, 2008 - Boston Scientific Corp. received CE Mark approval of its ACUITY Spiral left ventricular lead for use with cardiac resynchronization therapy defibrillators and cardiac resynchronization therapy pacemakers, marking the company�s seventh U.S. or European regulatory approval in the past nine weeks.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now